This is post hoc analysis from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization , Management , and Avoidance ( CHARISMA ) trial of 4772 patients with prior MI , 7804 patients with known atherothrombosis , and 2101 patients with risk factors alone but without heart failure .